Umsetzung von Leitlinien in der klinischen Praxis. Was können wir aus Klinischen Tumorregistern lernen? 2. Juni 2012 Marschner, N., Kopfmann, S., 2012. FORUM 27, 465–468. Bendamustine-Rituximab (BR) Replaces R-CHOP As “Standard of Care” in the Treatment of Indolent Non-Hodgkin Lymphoma in German Hematology Outpatient Centres. Knauf, W.U., Abenhardt, W., Nusch, A., Grugel, R., Marschner, N., 2012. Blood 120(21), 3666. Abstract… Weiterlesen Effectiveness of taxane- or anthracylin-based compared to taxane- and anthracyline-free 1st-line treatments in metastatic breast cancer patients in German oncology outpatient centres. Data from the clinical TMK Registry. Marschner, N., Tesch, H., Dörfel, S., Meyer, D., Petersen, V., Jänicke, M., 2012. Onkologie 35 (suppl 6)(P223), 68. doi:10.1159/000170919 Abstract… Weiterlesen